Literature DB >> 1434604

Implications of a pre-existing tumor hypoxic fraction on photodynamic therapy.

V H Fingar1, T J Wieman, Y J Park, B W Henderson.   

Abstract

The presence of oxygen in tissue is a requirement for photodynamic therapy (PDT)-induced destruction of solid tumors, otherwise no cell death occurs. Since many tumors have been shown to have significant populations of hypoxic cells, it is of clinical interest to determine if pre-existing tumor hypoxia limits phototherapy. This question was examined using RIF tumors where tumor response to PDT of completely oxygenated tumors was compared to tumors with an induced hypoxic fraction. Tumor hypoxia was induced by using vasoactive drugs (epinephrine, chlorpromazine, or isoproterenol), given 30 min prior to PDT, or by a surgical method. PDT consisted of 5 mg/kg Photofrin II ip 24 hr prior to treatment and 135 J/cm2 630-nm light. The administration of the various vasoactive agents induced hypoxic fractions of 2.2 to 10%. The surgical method induced hypoxic fractions of 35%. Tumor response and cure in animals given vasoactive agents did not differ from controls, suggesting that low levels of pre-existing tumor hypoxia do not limit photodynamic therapy in this tumor model. Animals with tumors made hypoxic by a surgical method showed significantly reduced tumor response to PDT. Only 14% of these animals had tumors which became flat and necrotic by the day following PDT, compared to nearly 100% for animals given vasoactive drugs or controls. Furthermore, no tumor cure was observed in animals treated by this method. The higher level of tumor hypoxia in these animals likely represents one point where large proportions of PDT-resistant cells can survive after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1434604     DOI: 10.1016/0022-4804(92)90101-5

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  9 in total

1.  A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy.

Authors:  Peng Mi; Daisuke Kokuryo; Horacio Cabral; Hailiang Wu; Yasuko Terada; Tsuneo Saga; Ichio Aoki; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  Nat Nanotechnol       Date:  2016-05-16       Impact factor: 39.213

Review 2.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

3.  In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light.

Authors:  Roger R Nani; Alexander P Gorka; Tadanobu Nagaya; Tsuyoshi Yamamoto; Joseph Ivanic; Hisataka Kobayashi; Martin J Schnermann
Journal:  ACS Cent Sci       Date:  2017-02-24       Impact factor: 14.553

4.  Transcriptional activation of HIF-1 by a ROS-ERK axis underlies the resistance to photodynamic therapy.

Authors:  María Julia Lamberti; María Florencia Pansa; Renzo Emanuel Vera; Martín Ernesto Fernández-Zapico; Natalia Belén Rumie Vittar; Viviana Alicia Rivarola
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

5.  Near-infrared uncaging or photosensitizing dictated by oxygen tension.

Authors:  Erin D Anderson; Alexander P Gorka; Martin J Schnermann
Journal:  Nat Commun       Date:  2016-11-17       Impact factor: 14.919

Review 6.  Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy.

Authors:  Jiangsheng Xu; James G Shamul; Elyahb Allie Kwizera; Xiaoming He
Journal:  Nanomaterials (Basel)       Date:  2022-02-23       Impact factor: 5.719

Review 7.  Photodynamic Therapy-Current Limitations and Novel Approaches.

Authors:  Gurcan Gunaydin; M Emre Gedik; Seylan Ayan
Journal:  Front Chem       Date:  2021-06-10       Impact factor: 5.221

8.  Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate.

Authors:  T M Sitnik; J A Hampton; B W Henderson
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

9.  Achieving efficient photodynamic therapy under both normoxia and hypoxia using cyclometalated Ru(ii) photosensitizer through type I photochemical process.

Authors:  Zhuang Lv; Huanjie Wei; Qing Li; Xianlong Su; Shujuan Liu; Kenneth Yin Zhang; Wen Lv; Qiang Zhao; Xianghong Li; Wei Huang
Journal:  Chem Sci       Date:  2017-10-31       Impact factor: 9.825

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.